Truveta’s new research explored the effectiveness of semaglutide (Ozempic) and tirzepatide (Mounjaro) in weight loss among patients with overweight or obesity. The study involved over 40,000 patients and used multiple methods, including propensity score matching, to create a balanced cohort of 18,000 patients. The findings revealed that tirzepatide is more effective than semaglutide in achieving significant weight loss, with patients on tirzepatide showing greater reductions in body weight at three months, six months, and one year. The study highlights the real-world effectiveness of these medications for weight loss, especially in advance of randomized clinical trials. Truveta’s research utilized extensive EHR data from a vast patient pool to provide timely insights into the effectiveness of these diabetes and obesity medications.
To read more, click here.
[Source: GlobeNewswire, November 27th, 2023]